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ABSTRACT  
 
Background  
Pneumococcal conjugate vaccines (PCVs) are highly effective in preventing 
pneumococcal invasive disease (IPD) due to serotypes included in the vaccines. The 
risk of vaccine-type IPD in immunised children (i.e. vaccine failure) has not been 
systematically assessed in countries with established PCV programmes.   
Methods 
We undertook a systematic review of the English literature published from January 
2000 to April 2016 to evaluate the vaccine schedule, risk factors, serotype 
distribution, clinical presentation and outcomes of vaccine failure in children 
vaccinated with the 7-valent (PCV7), 10-valent (PCV10), and 13-valent (PCV13) 
vaccines. Data sources included MEDLINE, EMBASE, Cochrane library, and 
references within identified articles.  
Results 
We identified 1,742 potential studies and included 20 publications involving 7,584 
participants in children aged 5 year-olds: 5,202 received 2 doses followed by a 
booster in 10 studies, (68.6%), 64 (0.8%) received 3 doses without a booster in 2 
studies, and 2,318 received a 3+1 schedule (30.6%) in 8 studies. A total of 159 
vaccine failure cases were identified, representing 2.1% [95% CI: 1.8%-2.4%] of the 
reported IPD cases. Most studies did not report clinical characteristics or outcomes. 
Among eight studies reporting comorbidities, 33/77 patients (42.9%) had an 
underlying condition. The main serotypes associated with vaccine failure were 19F 
(51/128 cases with known serotype; 39.8%), 6B (33/128; 25.8%), and 4 (10/128; 
7.8%). Only five studies reported patient outcomes, with a crude case fatality rate of 
2.4% (2/85; 95%CI: 0.3%-8.5%).  
Conclusion  
Pneumococcal conjugate vaccines have been implemented in national immunisation 
programmes for more than a decade, yet there are only a few studies reporting vaccine 
failure. PCV failure is rare, irrespective of vaccine or schedule. Co-morbidity 
prevalence was high amongst vaccine failure cases but case fatality rate was relatively 
low. There is a need for more systematic reporting vaccine failure cases in countries 
with established pneumococcal vaccination programmes.  
  
Introduction  
Pneumococcal conjugate vaccines (PCVs) have been widely introduced into 
childhood immunisation programmes in most industrialised countries. In 2000, the 7-
valent vaccine (PCV7) that protects against the seven most prevalent pneumococcal 
serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) causing invasive pneumococcal disease 
(IPD) in children was licensed. In 2010, PCV7 was replaced with a 13-valent vaccine 
(PCV13) that aimed to protect against six additional serotypes (1,3, 5, 6A, 7F, and 
19A). Another licensed PCV formulation, PCV10, that protects against serotypes 1, 5, 
and 7F in addition to PCV7 serotypes was also licensed at around the same time. 
Introduction of these vaccines into national childhood immunisation programmes has 
led to rapid and sustained declines in invasive pneumococcal disease (IPD) caused by 
the vaccine serotypes.
1
 
 
Little is known about the risk of vaccine-type IPD (VT-IPD) after completing the 
recommended course of PCV immunisation (i.e. vaccine failure). In children with 
Haemophilus influenzae type b (Hib) conjugate vaccine failure, 20% of those 
immunised before 12 months of age had a clinical risk factor for vaccine failure 
(prematurity, malignancy, dysmorphic or developmental delay, Down syndrome or 
neutropenia), 30% had immunological deficiency (total immunoglobulin and/or 
immunoglobulin subclass deficiency) and 44% had one or both risk factors.
2
 
Moreover, children who were vaccinated after 12 months of age were more likely to 
have one or both factors (67%). In contrast, the vast majority of children with group C 
meningococcal (MenC) conjugate vaccine failure were healthy prior to becoming 
unwell.
3
 A number of clinical, immunological and other chronic conditions are 
reported with an increased risk of IPD.
4
 Whether these conditions also increase the 
risk of PCV failure is not known. We, therefore, conducted a systematic review of 
published studies to evaluate the clinical presentation, co-morbidity status, serotype 
distribution and outcomes of PCV failure in children. It is hoped that the findings of 
this systematic review will provide clinicians with a robust evidence base to 
investigate and manage children suspected with pneumococcal vaccine failure. 
 
  
Methods 
Search Strategy 
A search strategy was designed to identify observational studies (cohort study, case-
control study, case series) reporting pneumococcal conjugate vaccine failure in 
children aged  5 year-olds who were immunised with PCVs in regions with 
established PCV immunisation programmes. We searched MEDLINE, EMBASE, and 
the Cochrane library from 1
st
 January 2000 to 30
th
 April 2016. We also searched the 
papers using the ISI web of knowledge, to identify relevant articles and conference 
proceedings. The medical subject headings (MeSH) terms used included 
“pneumococcal conjugate vaccines”, “pneumococcal conjugate vaccine failure”, 
“invasive pneumococcal disease”, “Streptococcus pneumoniae”, “pneumococcus”, 
“pneumococcal infection”, “child”, “infant”, “toddler”, “PCV7, “13vPCV”, “PCV9”, 
“PCV10”, “comorbidity”, and “risk factors”. The full search strategies have shown in 
Appendix 1. We only included studies published in English language in our review.  
In addition, we screened reference lists of selected papers to retrieve relevant studies.   
 
Study selection 
Studies were eligible for inclusion if they reported vaccine-type IPD in immunised 
children (i.e. vaccine failure) from observational studies and surveillance databases. 
Vaccine failure was defined as reported in the original articles; in general, the 
definition included cases of vaccine-type IPD after the primary course of 
immunisation (two or three doses) and/or after completing the full immunisation 
course, including the booster. Breakthrough cases with vaccine-type IPD in partially 
immunised children were not included in our study. Studies were excluded if they 
were case reports, laboratory or experimental studies, or not original research. Two 
independent reviewers (G.O. and S.L.) screened the title and abstract of papers 
identified by the electronic searches, evaluating inclusion and exclusion criteria for all 
papers. We retrieved full articles of included publications and each publication was 
then independently reviewed for eligibility. Discrepancies were resolved by 
discussion with a third author (Y. H.). 
 
Quality assessment and data extraction 
Two reviewers (G.O. and S.L.) independently reviewed the methodological quality of 
included studies, comparability of case and controls, and outcomes. The explanatory 
variables extracted included: study design, country, description of study subjects, 
vaccine schedule, serotype, underlying co-morbidity, clinical presentation and 
outcome of infection. The study quality assessment was undertaken according to the 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement for 
the conduct and reporting of systematic reviews.
5
  
 
Data analysis 
Included studies were summarised using descriptive analyses to provide an overview 
of the information on vaccine schedule, reported clinical presentations, underlying co-
morbidity, serotype distribution, and vaccine failure outcomes. We calculated the 
crude vaccine failure rate as the total number of vaccination failure cases divided by 
total number of reported IPD cases over the same period. We calculated the 
percentage with exact binomial 95% confidence interval (CI) for the outcome of 
interest where data were available.  
 
Results 
Study characteristics 
We identified 1,742 potential studies, of which 1,563 were excluded on the basis of 
title and abstracts (Figure 1). A further 106 duplicate studies and 53 additional studies 
did not meet eligibility criteria. One recent French study was excluded because it only 
evaluated vaccine failure among pneumococcal meningitis cases.
6
 The remaining 20 
studies were eligible and the full text was assessed for inclusion in the final review.
7-26
 
Five of the studies included older children, adults and the elderly population,
20-24
 but 
we were able to extract data for aged 5 year-olds. Most studies involved PCV7 
(70.0%; 14/20), one PCV10 (5.0%; 1/20), and one involved both PCV7 and PCV10 
(5.0; 1/20).  There was only one study reporting PCV13 failure (5.0%; 1/20). Most 
studies identified vaccine-type IPD cases through national and/or regional 
surveillance of IPD. Two Spanish studies identified IPD cases and vaccine failures 
among children admitted to the local paediatric hospitals.
8,26 
A summary of the study 
design, data collection method, study subjects, and definition of vaccine failure is 
presented in Table 1 and Table 2. The majority of studies did not report the ethnicity. 
A total of 7,584 participants aged  5 years who had received PCV in 20 studies were 
included in the final analysis (Table 2): 5,202 (68.6%) children in 10 studies received 
a two-dose priming schedule followed by a booster (2+1), 64 children (0.8%) children 
received three-dose priming schedule without a booster (3+0), and 2,318 (30.6%) 
children in 8 studies received three-dose priming schedule followed by a booster 
(3+1). One UK study reported vaccine failures after two priming doses as well as after 
the booster dose at 12-13 months of age.
17
 Two of the studies were case-control 
design. Ten studies (50.0%) were performed in Europe, 8 (40.0%) in North America, 
and 2 (10.0%) in Australia. There were no studies from developing countries.  
 
Overall, 159 vaccine failure cases were reported. None of the studies reported vaccine 
failure rates in the population (i.e using the total number of vaccinated children as the 
denominator). Of the children who developed IPD over a defined time period, 2.1% 
(95% CI: 1.8%-2.4%) were vaccine failures. Nine studies reported an underlying co-
morbidity in 33 of 77 (42.9%) vaccine failure cases. Two studies reported detailed co-
morbidities among vaccine failure cases.
11,27
 Of the eight studies that reported clinical 
presentation, 25 (43.1%; 25/58) cases had bacteraemia, 24 (41.4%; 24/58) had 
pneumonia, and 5 (8.6%; 5/58) had meningitis.  Only five studies reported patient 
outcomes, with a hospitalisation rate of 24.7% (21/85 patients) and a crude case 
fatality rate of 2.4% (2/85 patients; 95%CI: 0.3%-8.5%). The major serotypes 
associated with vaccine failure were 19F (39.8%; 51/128 cases with known serotype), 
followed by 6B (25.8%; 33/128), and 4 (7.8%; 10/128).  The only study on PCV13 
failure from Spain reported 3 children who developed PCV13-type IPD after a 
complete 4-dose immunisation schedule among 84 children aged 3-59 months 
diagnosed with IPD during 2012 and 2013.
26
 Notably, all three presented with 
complicated pneumonia and empyema; serotype 3 was responsible for two cases and 
serotype 19A for the third. A formal statistical analysis comparing the different 
vaccines and schedules was not performed because of small numbers of cases with 
limited information.   
 
Discussion 
A thorough systematic review of the literature identified a very low rate of childhood 
PCV failure in industrialised countries with established national immunisation 
programmes, irrespective of the conjugate vaccine or priming or boosting schedule 
used. Children with vaccine failure accounted for around 2% of total IPD cases and 
almost half had significant underlying comorbidities. Bacteraemia was the most 
common clinical presentation and the crude case-fatality rate among vaccine failure 
cases was very low at 2.4%.  
 
These findings confirm the high effectiveness of PCVs in preventing vaccine-type 
IPD in young children, who have a very high risk of serious bacterial infections. 
Moreover, conjugate vaccines can also induce herd protection by preventing carriage 
and onward transmission of vaccine serotypes to both vaccinated and unvaccinated 
children as well as adults and older adults.
27
 Over time, therefore, vaccine failure 
should become even less common as vaccine serotypes stop circulating in highly 
immunised populations. Serotypes 19F and 6B were responsible for more than two-
thirds of vaccine failure cases, perhaps because these two serotypes are the least 
immunogenic of the vaccine serotypes in infants and toddlers.
4, 11
 
 
 Co-morbidity prevalence in children with conjugate vaccine failure varies, depending 
on the disease responsible. In children with Hib vaccine failure, almost half had co-
morbidity and/or immunoglobulin deficiency.
2
 In contrast, the vast majority of 
children with MenC vaccine failure were previously healthy. Of the few published 
studies that reported comorbidity status in children with PCV7 or PCV10 vaccine 
failure, a third had co-morbidity. Only 2 of the studies listed the co-morbidities, with 
immunodeficiency and prematurity being the most prevalent.
7, 11
 These are known 
risk factors for IPD, irrespective of vaccination status and, therefore, it is not 
surprising that such children are also at increased risk of vaccine failure. In children 
with PCV failure and no comorbidities, we were unable to identify any study that 
systematically assessed their immunological status and, therefore, a potential as yet 
undiagnosed underlying immune deficiency cannot be excluded in this group. 
Recurrent IPD is rare, especially among vaccinated children, and most have an 
identifiable risk factor, such as asplenia, immunosuppression or cochlear implants,
17, 
28-31
 which is reassuring; however, children with recurrent IPD and no obvious risk 
factors are more likely to have an underlying immune deficiency, irrespective of their 
previous pneumococcal vaccination status.
32-34
 Such children, therefore, should be 
subjected to a thorough immunological assessment and investigation. 
 
The low overall hospitalisation rate of around 25% reported in five studies must be 
interpreted with caution. In countries such as the UK, blood cultures are usually only 
taken in patients presenting to hospital and, therefore, hospitalisation rates for IPD are 
always near 100%. In contrast, taking blood cultures in primary care is a common 
practice in the United States and, often, the children are treated with antibiotics as 
outpatients (68% of those younger than 5 years in 1998–99),35 hence the higher IPD 
incidence of 98.7/100,000 in the US compared with 31.8/100,000 population in 
England.
21
 It is possible that vaccinated children who develop vaccine-type IPD may 
have milder disease and better outcomes than unvaccinated children, but none of the 
published studies provided sufficient information to support this hypothesis 
 
Our results demonstrate the potential strengths of combining outcomes of rare events 
through a systematic review of the literature. However, the lack of information on 
vaccine failure cases in the observational studies was a significant limitation; 
consequently, we were unable to conduct any meta-analyses to compare differences in 
dosing schedules or calculate risks associated with clinical outcomes. Moreover, 
several publications utilised the same population-based surveillance to identify and 
report vaccine failure cases; this could potentially lead to double counting of the same 
cases. Given that PCV13 replaced PCV7 as far back as 2010, more data are needed on 
clinical characteristics, risk factors and outcomes of PCV13-type and non-vaccine 
type IPD in PCV13-immunised children. It is also important that future studies report 
vaccine failure rates using the total number of vaccinated children and their at-risk 
time period so that different vaccines, immunisation schedules and populations can be 
compared.  
 
Our study has identified a clear need to establish national and international registers 
for rare outcomes such as vaccine failure, as part of post-vaccine implementation 
surveillance in countries with established immunisation programmes. Standardising 
the collection and reporting for individual cases across regions and countries would 
further allow meaning analysis of the data collected, enabling valid comparison 
between different vaccines and schedules and to monitor trends over time.  
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Figure 1: Identification and selection of eligible studies in the systematic review 
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Table 1. Description of study design and reported vaccine failure definition  
Study  Country  Study design  Data collection Ethnicity  Vaccine schedule VF definition 
Dosing schedule 3+1      
 
 
Hsu et al. 2005 US Population- and laboratory- 
based surveillance 
Laboratories in Massachusetts send all S. 
pneumoniae to Department of Public Health 
White, Black, Hispanic, and 
Asian/Pacific islander  
2,4,6, and 12-15 mo Vaccine-related serotype IPD in a fully-vaccinated 
case 
Whitney et al. 2006 US Population- and laboratory-
based surveillance; matched 
case-control study 
CDC-ABCs White, Black, and Hispanic 2,4,6, and 12-15 mo Fully vaccinated cases who developed vaccine-
serotype IPD 
Callbo et al. 2006 Spain Retrospective study Local hospitals in Barcelona  Not reported 2,4,6, and 12-15 mo IPD caused by a vaccine serotype in a vaccinated 
patient 
Black et al. 2007 US Laboratory-based 
surveillance  
Northern California Kaiser Permanente 
Healthcare System  
White, Black, Asian, 
Hispanic, Native American, 
and Eskimo 
2,4,6, and 12-15 mo Fully vaccinated cases who developed vaccine-
serotype IPD 
Park et al. 2009 US Population-based 
surveillance  
CDC-ABCs White, Black, Asian, Native 
American/Alaska Native 
2,4,6, and 12-15 mo Vaccine-type IPD in a child who completed age-
appropriate PCV7 vaccination schedule as 
recommended by ACIP 
Ruckinger et al. 2009 Germany Population-based 
surveillance 
Hospital- and laboratory based surveillance 
system 
Not reported 2,3,4, and 12-15 mo Fully vaccinated IPD caused by vaccine serotype 
Kellner et al. 2009 Canada Prospective, population-
based surveillance  
Population-based surveillance in Calgary 
region 
Not reported 2,4,6, and 12-15 mo Fully vaccinated cases who developed vaccine-
serotype IPD 
Moraga et al. 2016 Spain Prospective study  Local paediatric hospitals in Barcelona area Not reported 2,4,6, and 12-15 mo IPD due to a PCV13 serotype in a fully-vaccinated 
child. IPD should have occurred 2 weeks or longer 
after the last dose of PCV13.  
Dosing schedule 3+0       
Hanna et al. 2010 Australia  Laboratory-based 
surveillance  
Diagnostic laboratories are required to 
notify all cases to their local public health 
units 
Non-Indigenous children 2, 4, and 6 mo Vaccine-type IPD in  fully immunised child; IPD 
defined as isolation of S. pneumoniae from sterile 
body site 
Lehmann et al. 2010 Australia Hospital-based surveillance 
& laboratory-based 
surveillance 
Surveillance involving all public and 
private hospitals in Western Australia 
3.5% Aboriginal vs 96.5% 
of non-Aboriginal 
2, 4, and 6 mo Vaccine-type IPD case in fully immunised children 
 
Dosing schedule 2+1       
Bettinger et al. 2010 Canada Surveillance study  Canadian immunization monitoring 
program, Active (IMPACT)  
Not reported 2,4, and 12 mo Invasive disease with a PCV7 isolate in a healthy 
child completely immunized according to national 
guidelines 
Deceunick et al. 2010 Canada Population-based study IPD cases reported by physicians and 
laboratories to public health authority in 
Quebec 
Not reported 2,4, and 12 mo Children who developed vaccine-serotype IPD 
Hanquet et al. 2011 Belgium Laboratory-based 
surveillance 
National reference laboratory Not reported Not reported Vaccine-type IPD in  fully immunised child; IPD 
defined as S. pneumoniae isolated from a sterile 
site in children aged <5 years 
de Wals et al. 2012 Canada Population-based ecological 
study 
Laboratory-based surveillance data  
 
Not reported 2+1 for low-risk infants (2, 
4, and 12 mo) 
3+1 for high-risk (2, 4, 6, 
and 12 mo) 
Vaccine-type IPD in  fully immunised child; 
Martinelli et al. 2013 Italy Hospital-based surveillance Computerized Immunization Registry 
(vaccination coverage) 
Prospective laboratory-confirmed 
surveillance (IPD cases among hospitalised 
children) 
Not reported 3, 5, and 12 mo Vaccine-type IPD in  fully immunised child; IPD 
defined as a child with isolation of S. pneumoniae 
by PCR positive sample from a  sterile body site 
Steens et al. 2013 Norway Observational retrospective 
population-based cohort 
study 
National Institute of Public Health; 
Norwegian Surveillance System for 
Communicable Diseases 
Not reported 3, 5, and 12 mo Vaccine-type IPD in  fully immunised child; IPD 
case defined as isolation of S. pneumoniae from a 
sterile body site 
Ladhani et al. 2013 UK National Surveillance Health Protection Agency Not reported 2, 4, and 12-13 mo PCV7 vaccine failure defined as PCV7-type IPD at 
least 14 days after 2 doses in <12 month-olds or 
after 1 dose in ≥12 month-olds.  
Harboe et al. 2013 Denmark Nationwide cohort study Laboratory surveillance data linked to the 
Danish Childhood Vaccination Registry 
Not reported 3, 5, and 12 mo Vaccine-type IPD as follows: (1) any child <13 mo 
and received 2 doses PCV7 or PCV13; (2) any 
child aged at least 12 months and completed the 
vaccination schedule; (3) any child at least 6 
months of age and received 2 doses of PCV7  
Harboe  et al. 2014 Denmark Population-based cohort 
study 
Laboratory surveillance data linked to the 
Danish Civil Registration System 
Not reported 3, 5, and 12 mo Vaccine-type IPD in  fully immunised child; IPD 
defined as S. pneumoniae was isolated from sterile 
body site 
Jokinen et al. 2015 Finland  Population-based, 
observational follow-up 
study 
National Infectious Disease Register  Not reported 3, 5, and 12 mo Vaccine-type IPD in  fully immunised child; IPD 
defined as isolation of S. pneumoniae by culture 
from blood or CSF and reported to the National 
Infectious Disease Register 
Abbreviations: IPD, invasive pneumococcal disease; mo, month; yr, year; CDC, the Centers for Disease Control and Prevention; ABCs, Active Bacterial Core Surveillance; CSF, Cerebrospinal fluid; ACIP, Advisory Committee on Immunization 
Practices; US, United State; UK, United Kingdom.  
  
Table 2: Characteristics of studies included in the systematic review  
  Country Age No. of study 
participants 
Vaccine  
 
VT-IPD* 
No. of cases 
Serotypes 
No. of cases 
Comorbidities§  
No. of cases   
Clinical presentations & complications 
No. of cases 
Clinical Outcomes 
Schedule 3+1 dosing          
Hsu et al. 2005 US <18yr 138 (aged <5yr) PCV7 11 6B: 2  
18C: 1  
19F: 5  
23F: 3   
3  Bacteraemia: 7 
URTI with bacteraemia: 1  
Peritonitis with bacteraemia: 1  
Abscess: 1  
Not reported 
Whitney et al. 2006 US 3 to 59 mo 782 PCV7 27 19F: 16  
4: 6  
Unknown: 5 
Not reported Not reported Not reported 
Callbo et al. 2006 Spain ≤ 5yr 121 PCV7 1 6A: 1 0  AOM with bacteraemia:1  Reported favourable outcomes 
without detailed description 
Black et al. 2007 US <5 yr 131 PCV7 3 19F: 1  
9V: 1  
4: 1  
Not reported Meningitis: 1  
Pneumonia with bacteraemia: 2  
Not reported 
Park et al. 2009 US < 5 yr 753 PCV7 27 6B: 9  
19F: 6  
9V: 4  
23F: 3 
14: 2  
4: 2  
18C: 1  
10  Pneumonia: 11  
Bacteraemia: 10  
Meningitis: 2  
Otitis: 2  
Endocarditis: 1  
Deep thigh abscess: 1  
 
Hospitalised: 18  
Died: 1 (with endocarditis) 
Ruckinger et al. 2009 Germany 0 to 15 yr 166 (aged <5yr) PCV7 4 19F: 2 
23F: 1 
4: 1 
Not reported Not reported Not reported 
Kellner et al. 2009 Canada all ages 143 (aged <5yr) PCV7 2 14: 1 
6B: 1 
2  Meningitis: 1 
Pneumonia: 1 
Not reported 
Moraga et al. 2016† Spain 3 to 59 mo 84 PCV13 9 3: 6 
6B: 1 
19A: 2  
Not reported  Complicated pneumonia: 8 
Empyema: 8 
Pneumothorax: 3 
Bronchoalveolar fistula: 2 
Bacteraemic mastoiditis: 1 
Septic shock: 1 
Epidural abscess & sigmoid sinus thrombosis: 1  
Not reported  
Schedule 3+0 dosing          
Lehmann et al. 2010 Australia All ages  40 (aged <5yr) PCV7 3 14: 1 
18C: 1 
19F: 1 
Not reported Not reported Not reported 
Hanna et al. 2010 Australia  All ages 24 (aged <5yr) PCV7 1 6B: 1 Not reported Not reported Not reported 
Schedule 2+1 dosing          
Bettinger et al. 2010 Canada <16 yr 1,138 (aged <5) PCV7 4 Unknown 0  Not reported Not reported 
Deceunick et al. 2010 Canada 2 to 59 mo 180 PCV7 2 Unknown 1  Not reported Not reported 
Hanquet et al. 2011 Belgium <5 yr 1,317 PCV7 1 18C: 1 1  Not reported Died: 0 
De Wals et al. 2012 Canada <5 yr 265 PCV7& PCV10 2 19F: 2 Not reported Not reported Not reported 
Martinelli et al. 2013 Italy 0 to 60 mo 159 PCV7 2 9V: 2 Not reported Pneumonia with bacteraemia: 2 Not reported 
Steens et al. 2013 Norway All ages  307 PCV7 2 6B: 1 
9V: 1 
Not reported Not reported Not reported 
Ladhani et al. 2013 UK 3 to 59 mo 1,342 PCV7 53 6B: 18  
19F: 16  
15  Not reported Died: 1 (with meningitis, 
immunodeficiency) 
Harboe et al. 2013 Denmark <5 yr 191 PCV7& PCV13 3 14: 1 
19F: 1 
23F: 1 
1  Bacteraemia: 1 
Meningitis: 1 
Hospitalised: 3 
Died: 0 
Harboe  et al. 2014 Denmark All ages 260 (aged <5yr) PCV7&PCV 13 1 Unknown Not reported Not reported Not reported 
Jokinen et al. 2015 Finland  0 to 5 yr 43 PCV10 1 19F: 1 Not reported Not reported Not reported 
Abbreviations: PCV: pneumococcal conjugate vaccine; US: United State; UK: United Kingdom; IPD, invasive pneumococcal disease; AOM: acute otitis media; URTI, upper respiratory tract infection. * VT-IPD: vaccine-type IPD. §co-morbidities 
in patients with treatment failure. †1 patient was administrated 2+1 schedule in a foreign country (Andorra); 1 patient received 3 dose of PCV7 at aged 3,5, and 7 months before receiving PCV13.  
